Full-Time

Quality Control Supervisor

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$88k - $110.3k/yr

Rensselaer, NY, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
ISO 9001
Word/Pages/Docs
Excel/Numbers/Sheets

Get referred to Curia

See people who can refer or advise you

Requirements
  • A Bachelor's degree in Chemistry, Analytical Chemistry, or a related field.
  • At least 5 years of experience in a current good manufacturing practice environment working with chromatography, including high-performance liquid chromatography, ultra-performance liquid chromatography, or gas chromatography, and extensive method development and/or validation experience.
  • At least 2 years of supervisory experience.
  • Strong oral and written communication skills, including effective listening.
  • Demonstrated ability to effectively utilize team resources.
  • Expertise in current good manufacturing practice, United States Pharmacopeia, European Pharmacopoeia, and Food and Drug Administration regulations.
  • Technical competence in the theory and interpretation of laboratory techniques.
  • Proficient use of computer software, including Microsoft Office Suite, Excel, Word, and other required software.
  • Strong organizational skills and the ability to multitask.
  • Proficiency in high-performance liquid chromatography and gas chromatography method development and method validation, with extensive experience using multiple other analytical techniques and analytical equipment.
  • Prior experience and knowledge of Food and Drug Administration good manufacturing practices, including 21 CFR parts 211, 820, and/or 600, and ISO 9001 and ISO 13485.
  • Ability to perform the essential functions of the job, including standing, walking, sitting, handling materials, reaching, occasional climbing or balancing, and lifting or moving up to 50 pounds.
  • Familiarity with applicable hazardous-waste training requirements under the Resource Conservation and Recovery Act, including waste labeling, secondary containment, chemical compatibility, storage limits, container limits, container integrity, and proper disposal of hazardous materials.
Responsibilities
  • Oversee routine and non-routine analytical chemistry assays of raw materials, in-process samples, finished active pharmaceutical ingredients, and special projects.
  • Manage the Quality Control team's analytical testing of incoming, in-process, and final products.
  • Ensure analytical chemistry functions comply with company and governmental safety and quality standards and that experimental documentation is complete and timely.
  • Supervise a team of scientists, including responsibility for motivation, education, efficiency, performance management, and productivity.
  • Ensure laboratory operations are conducted safely and remain familiar with the Chemical Hygiene Plan.
  • Maintain compliance with regulations and standard operating procedures, including current good manufacturing practices as necessary.
  • Organize workloads and coordinate activities across multiple concurrent projects according to established objectives, timelines, and deadlines.
  • Conduct investigations of out-of-specification results, deviations, change control management, and corrective and preventive actions.
  • Supervise and perform pharmaceutical analysis supporting drug product manufacturing.
  • Use required personal protective equipment when exposed to fumes, airborne particles, or toxic or caustic chemicals.
  • Generate hazardous waste for treatment, storage, and disposal in accordance with applicable requirements.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.